119 related articles for article (PubMed ID: 10537347)
21. Comparison of proliferating cell nuclear antigen immunostaining in lymph node metastases and primary prostate adenocarcinoma after neoadjuvant androgen deprivation therapy.
Minardi D; Galosi AB; Giannulis I; Montironi R; Polito M; Muzzonigro G
Scand J Urol Nephrol; 2004; 38(1):19-25. PubMed ID: 15204422
[TBL] [Abstract][Full Text] [Related]
22. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis.
Heidenreich A; Varga Z; Von Knobloch R
J Urol; 2002 Apr; 167(4):1681-6. PubMed ID: 11912387
[TBL] [Abstract][Full Text] [Related]
23. Lymph node positive prostate cancer: long-term survival data after radical prostatectomy.
Zwergel U; Lehmann J; Wullich B; Schreier U; Remberger K; Zwergel T; Stoeckle M
J Urol; 2004 Mar; 171(3):1128-31. PubMed ID: 14767285
[TBL] [Abstract][Full Text] [Related]
24. MIB-1, p53, bcl-2, and WAF-1 expression in pelvic lymph nodes and primary tumors in early stage cervical carcinomas: correlation with clinical outcome.
Graflund M; Sorbe B; Karlsson M
Int J Oncol; 2002 May; 20(5):1041-7. PubMed ID: 11956602
[TBL] [Abstract][Full Text] [Related]
25. Radical prostatectomy for clinical T4 prostate cancer.
Johnstone PA; Ward KC; Goodman M; Assikis V; Petros JA
Cancer; 2006 Jun; 106(12):2603-9. PubMed ID: 16700037
[TBL] [Abstract][Full Text] [Related]
26. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
[TBL] [Abstract][Full Text] [Related]
27. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
Amling CL; Blute ML; Bergstralh EJ; Seay TM; Slezak J; Zincke H
J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432
[TBL] [Abstract][Full Text] [Related]
28. Conventional assessment of needle biopsy specimens is more useful than digital image analysis of proliferation and DNA ploidy in prediction of positive surgical margins at radical prostatectomy.
Sengupta S; Cheville JC; Lohse CM; Zincke H; Myers RP; Riehle DL; Pankratz VS; Blute ML; Sebo TJ
Urology; 2006 Jul; 68(1):94-8. PubMed ID: 16844452
[TBL] [Abstract][Full Text] [Related]
29. Isolated seminal vesicle invasion imparts better outcomes after radical retropubic prostatectomy for clinically localized prostate cancer: prognostic stratification of pt3b disease by nodal and margin status.
Masterson TA; Pettus JA; Middleton RG; Stephenson RA
Urology; 2005 Jul; 66(1):152-5. PubMed ID: 15992904
[TBL] [Abstract][Full Text] [Related]
30. Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer.
Stattin P; Damber JE; Karlberg L; Bergh A
J Urol; 1997 Jan; 157(1):219-22. PubMed ID: 8976256
[TBL] [Abstract][Full Text] [Related]
31. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival.
Tollefson MK; Leibovich BC; Slezak JM; Zincke H; Blute ML
J Urol; 2006 Feb; 175(2):547-51. PubMed ID: 16406993
[TBL] [Abstract][Full Text] [Related]
32. p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer.
Revelos K; Petraki C; Gregorakis A; Scorilas A; Papanastasiou P; Tenta R; Koutsilieris M
In Vivo; 2005; 19(5):911-20. PubMed ID: 16097446
[TBL] [Abstract][Full Text] [Related]
33. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients.
Satoh T; Yang G; Egawa S; Addai J; Frolov A; Kuwao S; Timme TL; Baba S; Thompson TC
Cancer; 2003 Mar; 97(5):1225-33. PubMed ID: 12599229
[TBL] [Abstract][Full Text] [Related]
34. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
[TBL] [Abstract][Full Text] [Related]
35. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
[TBL] [Abstract][Full Text] [Related]
36. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10.
Li R; Heydon K; Hammond ME; Grignon DJ; Roach M; Wolkov HB; Sandler HM; Shipley WU; Pollack A
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4118-24. PubMed ID: 15217948
[TBL] [Abstract][Full Text] [Related]
37. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era.
Gjertson CK; Asher KP; Sclar JD; Goluboff ET; Olsson CA; Benson MC; McKiernan JM
Urology; 2007 Oct; 70(4):723-7. PubMed ID: 17991544
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
Abaza R; Diaz LK; Laskin WB; Pins MR
J Urol; 2006 Dec; 176(6 Pt 1):2701-5. PubMed ID: 17085199
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
May M; Siegsmund M; Hammermann F; Loy V; Gunia S
Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
[TBL] [Abstract][Full Text] [Related]
40. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
